Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 19, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions.
| Instrument | Transaction Date | Price | Volume |
|---|---|---|---|
| Ordinary Shares (GBP) | 2017-04-13 | £16.39 | Multiple transactions ranging from 230,011 to 575,028 shares |
| American Depositary Shares (USD) | 2017-04-13 | $41.8150 | 359,648 ADSs |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine increases in notional interest in shares for specific executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions reported are mechanical increases in notional share interests resulting from the re-investment of dividends paid on April 13, 2017, under the Company's Deferred Investment Award Programme.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions are non-discretionary dividend re-investments, not open market purchases or sales.
- Executives Involved: Transactions were recorded for Ms. E. Walmsley (CEO), Mr. R. G. Connor (President, Global Manufacturing & Supply), Mr. S. A. Hussain (President, Global Pharmaceuticals), Mr. B. McNamara (CEO, GSK Consumer Healthcare), Mr. D. S. Redfern (Chief Strategy Officer), Ms. C. Thomas (SVP, HR), and Dr. P. J. T. Vallance (President, R&D).
- Share Price: The Ordinary Share price at the time of transaction was £16.39, and the ADS price was $41.8150.
- Dividend Date: The underlying dividends were paid on April 13, 2017.